At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,553 enrolled
Drug / intervention
Fixed Combination Bimatoprost and Timololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
In Brief
An observational study evaluating Fixed Combination Bimatoprost and Timolol for Glaucoma, Primary Open Angle and Ocular Hypertension. Completed, enrolled 1,553 participants across 1 site.
Detailed Summary
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Primary Open Angle, Ocular Hypertension
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedDec 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedDec 3, 2013
Enrollment StartNov 25, 2013
Primary CompletionDec 19, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.6 years ago
Interventions
Fixed Combination Bimatoprost and Timololdrug
Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.